Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure

Fig. 2The alternative text for this image may have been generated using AI.

Blood lipids and coagulation. Principal component analysis (PCA) of laboratory parameters shown in two dimensions based on (a) patient group and visit and (b) key contributing indicators; in panel (b), cos² values indicate the relative contribution of each indicator to the principal components. c Heat map depicting baseline-relative changes in blood lipid and coagulation indicators across all visits; representative indicators are highlighted in red. d Raw serum D-dimer and international normalized ratio (INR) values at each visit. V0 denotes the 1st MSC infusion; V5 denotes the 2nd MSC infusion; and V8 denotes the 3rd MSC infusion. e Serum total cholesterol (CHOL) and small dense LDL (sLDL) levels at each visit. Dashed lines denote the upper limit of normal. Statistical significance in (d) and (e) was assessed using baseline-adjusted repeated-measures analysis of variance (ANOVA). Data are presented as mean ± SEM. Red P values indicate P < α (0.05)

Back to article page